Osmovist 190 side effects by duration, gender and age - a phase IV clinical study of FDA data

Summary:

Side effects are reported by people who take Osmovist 190. Common side effects include posterior reversible encephalopathy syndrome among females.

The phase IV clinical study is created by eHealthMe based on 1 report from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 16, 2022

1 person who takes Osmovist 190 and has side effects is studied.


What is Osmovist 190?

Osmovist 190 has active ingredients of iotrolan. eHealthMe is studying from 1 Osmovist 190 user for its effectiveness, alternative drugs and more.

Number of Osmovist 190 reports submitted per year:

Osmovist 190 side effects.

Osmovist 190 side effects by gender *:

female:

  1. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)

male:

n/a

Osmovist 190 side effects by age (0-1 to 60+) *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Osmovist 190?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



How the study uses the data?

The study is based on iotrolan (the active ingredients of Osmovist 190) and Osmovist 190 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

Related studies

Alternative drugs to, pros and cons of Osmovist 190:

All Osmovist 190 side effects from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: